EGF and neoplasm: EGF may also be involved in reducing docetaxel efficacy in cancer cells; however, a number of other molecules including IL-6 [68, 69], TGFβ [70], CXCL12 [64], CCL21 [71], VEGF [72], among others secreted by activated lymphatics are known contributors to drug resistance and these interactions may be tumor cell specific.